Polar Capital Global Health Tst PLC Top Ten Equity Holdings and Exposures

RNS Number : 3913P

Polar Capital Global Health Tst PLC

09 December 2024

 

9^th December 2024

 

Polar Capital Global Healthcare Trust plc (the "Company")

 

Top Ten Equity Holdings and Sector and Geographic Exposure as at 29^th November 2024 full Portfolio listing as at 31^st October 2024 available from company's website.

 

Polar Capital Global Healthcare Trust plc is pleased to announce that as at 29^th November 2024 the top ten equity holdings and the sector and geographic breakdown were as follows:

 

Top 10 Holdings	%
UnitedHealth Group	8.0%
Eli Lilly & Co	7.9%
Novo Nordisk A/S	5.9%
AbbVie	4.6%
Roche	4.3%
UCB	4.0%
Sanofi	3.7%
Terumo Corp	3.7%
Sandoz Group AG	3.6%
Intuitive Surgical	3.5%
Total	49.2%

 

Sector Exposure	%
Pharmaceuticals	32.2%
Biotechnology	20.3%
Healthcare Equipment	16.3%
Managed Healthcare	8.0%
Life Sciences Tools & Services	7.2%
Healthcare Supplies	5.5%
Healthcare Services	3.2%
Healthcare Technology	2.6%
Healthcare Facilities	2.1%
Metal, Glass & Plastic Containers	1.9%
Healthcare Distributors	0.8%
Cash	0.0%
Total	100.0%

 

Geographic Exposure	%
United States	45.4%
Switzerland	12.9%
Denmark	11.0%
Japan	6.3%
France	6.0%
Belgium	4.0%
Germany	3.2%
Netherlands	3.0%
Sweden	2.8%
United Kingdom	2.6%
Italy	2.1%
Ireland	0.8%
Cash	0.0%
Total	100.0%

 

The monthly factsheet will usually be available on the Company's website on the 10^th working day after the month end and includes a commentary by the investment manager.  www.Polarcapitalhealthcaretrust.com

Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

PFUUPGGPPUPCGQB